SCHEMBL6515252

SCHEMBL6515252

CC/C(=C\C(=O)O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 8/20 0.51
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
CES2 O00748 2/20 0.50
CES1 P23141 2/20 0.50
HDAC3 O15379 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ESR1 P03372 1/20 0.42
PGR P06401 1/20 0.42
ESR2 Q92731 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MTNR1A P48039 2/20 0.42
MTNR1B P49286 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303273 1.00 PDPK1 (0.51) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL2303277 1.00 PDPK1 (0.51) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL7486774 0.91 ESR1 (0.44) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL29119393 0.86 ALDH1A1 (0.50) SMN1; SMN2HPGDESR1ESR2MEN1
SCHEMBL1381134 0.86 HDAC1 (0.52) HDAC1HDAC2CES2CES1HDAC3
SCHEMBL13290283 0.86 HDAC1 (0.69) HDAC1HDAC2CES2CES1HDAC3
SCHEMBL16721092 0.84 PDPK1 (0.57) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL11323281 0.84 PDPK1 (0.57) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL16721081 0.84 PDPK1 (0.57) PDPK1HDAC1HDAC2CES2CES1
SCHEMBL10350158 0.84 ESR1 (0.56) CES2MAPTSMN1; SMN2CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065349-A1 Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems BUCHWALD STEPHEN L (US) 2005-03-24 US disclosed
US-6787655-B2 TRANSITION-METAL-CATALYZED ASYMMETRIC 1,4-ADDITION OF A NUCLEOPHILE, E.G., HYDRIDE, TO CYCLIC AND ACYCLIC ENOATES AND ENONES AND THE CATALYST CONTAINING A COPPER AND AN ASYMMETRIC BIDENTATE BISPHOSPHINE LIGAND MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-09-07 US disclosed
US-20030125563-A1 Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-03 US disclosed
US-6465664-B1 CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-10-15 US disclosed
WO-2001019761-A2 ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-03-22 WO disclosed
CN-1005711-B Preparation method of phenoxypropanolamine compounds 弗·哈夫曼-拉罗彻公司 1989-11-08 CN disclosed
EP-0057444-B1 DICHLOROAMINO ACID DERIVATIVES USEFUL AS POTENT GERMICIDAL AND FUNGICIDAL AGENTS MERCK & CO. INC. (US) 1986-05-07 EP disclosed
US-4386103-A ENVIRONMENT, FOOD TREATMENT, PERSONAL OR VETERINARY HYGIENE MERCK & CO., INC. (US) 1983-05-31 US disclosed
EP-0057444-A2 Dichloroamino acid derivatives useful as potent germicidal and fungicidal agents MERCK & CO. INC. (US) 1982-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065349-A1 Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems APEX1, AP2A1, ENPP1 PDPK1 1459/4885HDAC1 999/4885HDAC2 1286/4885
US-20030125563-A1 Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems APEX1, AP2A1, ENPP1 PDPK1 1459/4885HDAC1 999/4885HDAC2 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.